← Back to Search

Monoclonal Antibodies

SL-172154 for Ovarian Cancer

Phase 1

Waitlist Available

Research Sponsored by Shattuck Labs, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 24 months

Awards & highlights

Study Summary

This trial is testing a new drug for ovarian cancer to see if it is safe and effective.

Eligible Conditions

Ovarian Cancer
Peritoneal Carcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum Tolerated Dose (MTD) of SL-172154

Safety profile of SL-172154

Secondary outcome measures

Area under the serum concentration-time curve (AUC)

Assess preliminary evidence of anti-tumor activity of SL-172154

Clearance (CL)

+7 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: SL-172154Experimental Treatment1 Intervention

Intravenous administration

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

SL-172154

2020

Completed Phase 1

~40

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Shattuck Labs, Inc.Lead Sponsor

4 Previous Clinical Trials

354 Total Patients Enrolled

1 Trials studying Ovarian Cancer

102 Patients Enrolled for Ovarian Cancer

Shattuck LabsStudy DirectorShattuck Labs

4 Previous Clinical Trials

354 Total Patients Enrolled

1 Trials studying Ovarian Cancer

102 Patients Enrolled for Ovarian Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent has SL-172154 been associated with adverse health effects?

"SL-172154's safety has been evaluated to a level 1 on our scale, given that we are currently in the early stages of testing and lack sufficient data regarding its efficacy."

Answered by AI

Are there any openings available for new participants in this trial?

"Clinicaltrials.gov has indicated that this study, which was initially posted on June 29th 2020 and last updated on November 15th 2022, is not currently in search of participants. Despite this fact, there are 692 active medical studies actively recruiting individuals."

Answered by AI

How many facilities are actively administering this research?

"Participants in this research study will be recruited from Sarah Cannon Research Institute, START Mountain Region, City of Hope, and 6 other sites. The former two institutions are located in Nashville (TN) and West Valley City (UT), while the latter can be found in Duarte (CA)."

Answered by AI

What objectives is this experiment striving to accomplish?

"Shattuck Labs, Inc., the trial sponsor, has specified that its primary outcome is to observe the safety profile of SL-172154 over a period from Day 1 to 90 days after Last Dose. Amongst secondary objectives are determining Tmax (time at which maximum concentration of SL-172154 is observed), Cmax (maximum serum concentration) and immunogenicity levels in participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

2020. "Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04406623.